Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026
← Back to Research Index
Compare Evaluate Matrix Half-Life
Dossier · № 37 of 110 Updated Nov 17, 2026

VIP

Vasoactive Intestinal Peptide · Aviptadil

PHASE 3 (AVIPTADIL) / OFF-LABEL · NEUROPEPTIDE HORMONE; MULTI-ORGAN REGULATOR

▓ 161 indexed citations across PubMed (142), ClinicalTrials.gov (4), EuropePMC (15).

Citation breakdown by evidence tier

← weaker evidence  ·  stronger evidence →

161 citations across 9 tiers

Tap any tier to jump to that section of the bibliography.

Background

A very important person or personage is a person who is accorded special privileges due to their high social rank, status, influence, or importance. The term was not common until sometime after World War II when it was popularised by Royal Air Force pilots.

→ Wikipedia

Mechanism of action

VPAC1/VPAC2 receptor agonist; vasodilation; anti-inflammatory; surfactant production

Researched effects

Vasodilation; anti-inflammatory; gut function; ARDS (COVID trials); CIRS research

Reported efficacy (trial readout)

  • Mortality Reduction 58%

    Aviptadil in COVID-19 pn (n=80)

    Medium confidencen=802025

Trial-efficacy data current as of November 16, 2026.

Live evidence

Recent literature

Live signals refreshed daily. Current as of November 19, 2026.

Dosing reported in literature

Intranasal 50-100 mcg 4x daily (off-label); IV in COVID trials

Known concerns

Hypotension; flushing; diarrhea

Top-ranked picks

10 pre-curated authoritative sources, ranked by journal tier and study weight.

  1. Aviptadil Therapy in Acute Respiratory Distress Syndrome Patients: A Systematic Review and Meta-analysis.

    Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2025 — META-ANALYSES · AUTHORITY 94.5

  2. Vasoactive intestinal Peptide as a diagnostic or prognostic biomarker in multiple sclerosis: A systematic review.

    Multiple sclerosis and related disorders · 2026 — SYSTEMATIC REVIEWS · AUTHORITY 84.5

  3. Inhaled Aviptadil Is a New Hope for Recovery of Lung Damage due to COVID-19.

    Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2025 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 74.5

  4. Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial.

    The Lancet. Respiratory medicine · 2023 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 74.3

  5. The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial.

    Critical care medicine · 2022 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 74.2

  6. A Clinical Study Evaluating Inhaled Aviptadil on COVID-19

    2021 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 73.1

  7. Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial.

    Trials · 2022 — CLINICAL TRIALS · AUTHORITY 69.2

  8. Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

    2020 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 69.0

  9. Vasoactive intestinal peptide fragment VIP10-28 and active vasodilation in human skin.

    Journal of applied physiology (Bethesda, Md. : 1985) · 2005 — CLINICAL TRIALS · AUTHORITY 67.5

  10. Evidence for a role for vasoactive intestinal peptide in active vasodilatation in the cutaneous vasculature of humans.

    The Journal of physiology · 2003 — CLINICAL TRIALS · AUTHORITY 67.3

Full citation library

Year distribution

Meta-Analyses

1
  1. 1.

    Udupa AA, Todur P, Chaudhuri S, Gupta N, et al. · Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2025 · PMID 41368449

    Acute respiratory distress syndrome (ARDS) is a life-threatening condition with a high mortality rate despite advances in supportive care. Aviptadil, a synthetic analogue of vasoactive intestinal peptide (VIP), exhibits anti-inflammatory potential and cytoprotective effects that may improve pulmonary function. However, its role in improving survival among ARDS patients remains uncertain. This systematic review and meta-analysis aimed to evaluate the effectiveness of aviptadil in improving surviv…

Systematic Reviews

1
  1. 2.

    Cabrera-Martín A, Juarranz Y, Gutiérrez-Cañas I, Martínez C · Multiple sclerosis and related disorders · 2026 · PMID 42447728

    Biomarkers are crucial in multiple sclerosis (MS) to improve diagnosis, prognosis, and disease monitoring in this heterogeneous immune-mediated disorder. Vasoactive intestinal peptide (VIP) is an immunomodulatory and neuroprotective neuropeptide with established effects in preclinical models, but its biomarker utility remains uncertain. This review evaluated VIP expression as an MS biomarker. A systematic search of PubMed, Embase, and Cochrane databases was conducted according to PRISMA guidelin…

Randomised Controlled Trials

3
  1. 3.

    Brown SM, Barkauskas CE, Grund B, Sharma S, et al. · The Lancet. Respiratory medicine · 2023 · PMID 37348524

    There is a clinical need for therapeutics for COVID-19 patients with acute hypoxemic respiratory failure whose 60-day mortality remains at 30-50%. Aviptadil, a lung-protective neuropeptide, and remdesivir, a nucleotide prodrug of an adenosine analog, were compared with placebo among patients with COVID-19 acute hypoxaemic respiratory failure. TESICO was a randomised trial of aviptadil and remdesivir versus placebo at 28 sites in the USA. Hospitalised adult patients were eligible for the study if…

  2. 4.

    Esendagli D, Sarı N, Akhan S, Arslan S, et al. · Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2025 · PMID 39870064

    We are still in search of new therapeutic options for COVID-19 to prevent new infections, enable fast recovery, and reduce the long-lasting symptoms or sequelae. This study aimed to investigate the short- and long-term effects of inhaled aviptadil on hospitalized, adult COVID-19 patients. A multicenter, prospective, placebo-controlled, comparative, randomized, double-blind clinical trial was conducted. Patients were randomized 1:1 to either inhaled aviptadil or placebo, in addition to the standa…

  3. 5.

    Youssef JG, Lavin P, Schoenfeld DA, Lee RA, et al. · Critical care medicine · 2022 · PMID 36044317

    Respiratory failure is a lethal complication of COVID-19 that has remained resistant to drug therapy. Vasoactive intestinal peptide (VIP) is shown in nonclinical studies to upregulate surfactant production, inhibit cytokine synthesis, prevent cytopathy, and block replication of the severe acute respiratory syndrome coronavirus 2 virus in pulmonary cells. The study aims to determine whether Aviptadil (synthetic VIP) can improve survival and recovery in patients with COVID-19 respiratory failure c…

Clinical Trials

3
  1. 6.

    Boesing M, Abig K, Brändle M, Brutsche M, et al. · Trials · 2022 · PMID 36127739

    Despite the fast establishment of new therapeutic agents in the management of COVID-19 and large-scale vaccination campaigns since the beginning of the SARS-CoV-2 pandemic in early 2020, severe disease courses still represent a threat, especially to patients with risk factors. This indicates the need for alternative strategies to prevent respiratory complications like acute respiratory distress syndrome (ARDS) associated with COVID-19. Aviptadil, a synthetic form of human vasoactive intestinal p…

  2. 7.

    Wilkins BW, Wong BJ, Tublitz NJ, McCord GR, et al. · Journal of applied physiology (Bethesda, Md. : 1985) · 2005 · PMID 16109832

    A recent study reported the vasoactive intestinal peptide (VIP) fragment VIP(10-28) inhibited the rise in skin blood flow during heat stress. Our laboratory has reported that the nitric oxide (NO) pathway and histamine receptor-1 (H1)-receptor activation is common to both exogenous VIP-mediated dilation and active vasodilation (AVD). The present study aimed to further examine the specific role for VIP in AVD by using VIP(10-28) to antagonize VIP-mediated dilation in the presence of NO synthase (…

  3. 8.

    Bennett LA, Johnson JM, Stephens DP, Saad AR, et al. · The Journal of physiology · 2003 · PMID 12847205

    Active vasodilatation (AVD) in human, non-glabrous skin depends on functional cholinergic fibres but not on acetylcholine (ACh). We tested whether AVD is a redundant system in which ACh and vasoactive intestinal polypeptide (VIP) are co-released from cholinergic nerves. (1) We administered VIP by intradermal microdialysis to four discrete areas of skin in the presence of different levels of the VIP receptor antagonist, VIP(10-28), also delivered by microdialysis. Skin blood flow (SkBF) was conti…

Trial Registrations (ClinicalTrials.gov)

4
  1. 9.
  2. 10.

    NCT04260035 · NA · Completed · 2020

    Conditions: Migraine, Pain, Neurologic Manifestations (+3)

  3. 11.

    NCT01471990 · NA · Completed · 2011

    Conditions: Migraine Without Aura

  4. 12.

    NCT04844580 · Phase 2 · Completed · 2021

    Conditions: Covid19

Reviews

21
  1. 13.

    Mukherjee T, Behl T, Sharma S, Sehgal A, et al. · Environmental science and pollution research international · 2022 · PMID 34846667

    Vasoactive intestinal peptide (VIP) is a neuropeptide that is produced by the lymphoid cells and plays a major role in immunological functions for controlling the homeostasis of the immune system. VIP has been identified as a potent anti-inflammatory factor, in boosting both innate and adaptive immunity. Since December 2019, SARS-Cov-2 was found responsible for the disease COVID-19 which has spread worldwide. No specific therapies or 100% effective vaccines are yet available for the treatment of…

  2. 14.

    Keijzers GB · Current opinion in investigational drugs (London, England : 2000) · 2001 · PMID 11566015

    Aviptadil is an injectable formulation of vasoactive intestinal polypeptide (VIP) in combination with the adrenergic drug phentolamine. Aviptadil in combination with phentolamine and sexual stimulation, is expected to provide a new and effective alternative for erectile dysfunction (ED) patients that is essentially free of the troublesome side effects and cumbersome delivery methods which limit the use of other pharmacologic preparations. Aviptadil can be delivered using Senetek's novel and pate…

  3. 15.

    Hill JM, McCune SK, Alvero RJ, Glazner GW, et al. · Annals of the New York Academy of Sciences · 1996 · PMID 8993408

    Vasoactive intestinal peptide (VIP) plays a regulatory role in the growth of early postimplantation rodent embryos through its action on receptors localized to the central nervous system (CNS). However, the origin of the VIP influencing embryonic growth is unknown. VIP binding sites have been found prenatally; however, VIP mRNA was not detected in the rat CNS before birth and has been detected in peripheral organs only during the final third of gestation. Recent studies have revealed that VIP re…

  4. 16.

    Groneberg DA, Springer J, Fischer A · Pulmonary pharmacology & therapeutics · 2001 · PMID 11603952

    Vasoactive intestinal polypeptide (VIP) is one of the most abundant, biologically active peptides found in the human lung. VIP is a likely neurotransmitter or neuromodulator of the inhibitory non-adrenergic non-cholinergic airway nervous system and influences many aspects of pulmonary biology. In human airways VIP-immunoreactive nerve fibres are present in the tracheobronchial airway smooth muscle layer, the walls of pulmonary and bronchial vessels and around submucosal glands. Next to its promi…

  5. 17.

    Luis J, Martin JM, el Battari A, Marvaldi J, et al. · Biochimie · 1988 · PMID 2852963

    Vasoactive intestinal peptide (VIP) is a neuropeptide with a broad range of biological activities in various tissues. After interaction with its membrane receptor, VIP generally induces a very large increase in the intracellular cyclic AMP level. Receptors for VIP have been described in numerous tissues and cell lines. The first results on VIP receptor structure have been obtained by covalent cross-linking using bifunctional reagents. The molecular mass of the different components characterized…

  6. 18.

    Delgado M, Ganea D · Amino acids · 2013 · PMID 22139413

    Vasoactive intestinal peptide (VIP), a 28-amino acid neuropeptide/neurotransmitter, is widely distributed in both the central and peripheral nervous system. VIP is released by both neurons and immune cells. Various cell types, including immune cells, express VIP receptors. VIP has pleiotropic effects as a neurotransmitter, immune regulator, vasodilator and secretagogue. This review is focused on VIP production and effects on immune cells, VIP receptor signaling as related to immune functions, an…

  7. 19.

    Verma AK, Manohar M, Upparahalli Venkateshaiah S, Mishra A · Cytokine & growth factor reviews · 2017 · PMID 28964637

    Worldwide increase incidences of allergic diseases have heightened the interest of clinicians and researchers to understand the role of neuroendocrine cells in the recruitment and activation of inflammatory cells. Several pieces of evidence revealed the association of neuropeptides in the pathogenesis of allergic diseases. Importantly, one such peptide that is secreted by neuronal cells and immune cells exerts a wide spectrum of immunological functions as cytokine/chemokine is termed as Vasoacti…

  8. 20.

    Davidson A, Moody TW, Gozes I · Journal of molecular neuroscience : MN · 1996 · PMID 8873894

    Vasoactive intestinal peptide (VIP) is a neuropeptide of multiple functions affecting development and aging. In cancer, for example, VIP was found to function as an autocrine growth factor in nonsmall cell lung cancer (NSCLC) promotion. Furthermore, a VIP hybrid antagonist (neurotensin(6-11)-VIP(7-28)) was found to inhibit NSCLC growth. In the present study, the expression of VIP mRNA was studied using human lung cancer cells. RNA prepared from 19 cell lines was fractionated by 1% agarose gel el…

  9. 21.

    Spong CY, Lee SJ, McCune SK, Gibney G, et al. · Annals of the New York Academy of Sciences · 1999 · PMID 10676439

    Vasoactive intestinal peptide (VIP) is an identified regulator of growth in the embryonic day (E) 9-11 mouse. Mouse embryonic and extra-embryonic tissues were studied to identify the source of VIP at this critical time. VIP and mRNA was detected in the decidua/trophoblast at E8 and declined until E10, after which it was not detectable. VIP mRNA was not apparent in the embryo until E11-E12. At E9, cells in decidua had VIP as well as lymphocyte marker (delta and CD3) immunoreactivity. VIP binding…

  10. 22.

    Porter JP, Ganong WF · Annals of the New York Academy of Sciences · 1988 · PMID 3291698

    VIP has now been shown to produce an increase in renin release in a number of species, including humans. Our work suggests that VIP is capable of producing this effect by a direct action on the renin-secreting juxtaglomerular cells of the kidney. We have found no evidence to support the possibility that VIP produces this effect as a neurotransmitter in the kidney. In this regard, it should be noted that VIP has been identified as a cotransmitter primarily in cholinergic neurons. The kidney is th…

  11. 23.

    Bellinger DL, Lorton D, Brouxhon S, Felten S, et al. · Advances in neuroimmunology · 1996 · PMID 8790778

    Evidence for VIP influences on immune function comes from studies demonstrating VIP-ir nerves in lymphoid organs in intimate anatomical association with elements of the immune system, the presence of high-affinity receptors for VIP, and functional studies where VIP influences a variety of immune responses. Anatomical studies that examine the relationship between VIP-containing nerves and subpopulations of immune effector cells provide evidence for potential target cells. Additionally, the presen…

  12. 24.

    Christophe J, Svoboda M, Waelbroeck M, Winand J, et al. · Annals of the New York Academy of Sciences · 1988 · PMID 2839079

    In purified rat pancreatic plasma membranes, (D-Phe4)PHI interacts as a selective VIP agonist for rat pancreatic VIP-preferring receptors, based on binding selectivity and adenylate cyclase activation, therefore allowing us to discriminate between the participation of VIP-preferring and secretin-preferring receptors in VIP stimulation. VIP-preferring receptors also bind GRF. They rely on disulfide bridges for their functional integrity. Their coupling with adenylate cyclase, based on the intrins…

  13. 25.

    Leceta J, Martínez C, Delgado M, Garrido E, et al. · Advances in neuroimmunology · 1996 · PMID 8790779

    Experimental evidence is accumulating showing that vasoactive intestinal peptide (VIP) acts as an immunoregulatory peptide. Findings from our laboratory and others indicate that cells of the immune system are able to produce VIP. We have detected immunoreactivity for VIP in lymphocytes by immunohistochemical methods at specific locations of both central and peripheral lymphoid organs. Double immunofluorescence staining and flow cytometry analysis indicate that both T and B lymphocytes contain VI…

  14. 26.

    Porst H, Lewis R, Virag R, Goldstein I · Sexual medicine reviews · 2024 · PMID 38644056

    Although oral phosphodiesterase 5 inhibitors represent a first choice and long-term option for about half of all patients with erectile dysfunction (ED), self-injection therapy with vasoactive drugs remains a viable alternative for all those who are not reacting or cannot tolerate oral drug therapy. This current injection therapy has an interesting history beginning in 1982. To provide a comprehensive history of self-injection therapy from the very beginnings in 1982 by contemporary witnesses an…

  15. 27.

    Gozes I, Furman S · Current pharmaceutical design · 2003 · PMID 12570811

    The following review outlines the physiological outcome of VIP and VIP gene manipulations. Previously, we reviewed the various VIP receptors associated with biological functions ranging from growth regulation, sexual function, bronchodilation, vasodilation and immune interactions to neurotrophism. VIP-based drug design is discussed below.

  16. 28.

    Fahrenkrug J · Digestion · 1979 · PMID 39014

    Vasoactive intestinal polypeptide (VIP) is a highly basic octacosapeptide isolated from porcine small intestine. VIP was originally considered to be a gut hormone, but radioimmunochemical and immunohistochemical studies have revealed that VIP has a widespread distribution localized in neurons. VIP-containing neurons are present in the central nervous system including the cerebral arteries, the digestive tract, the genitourinary tract and the adrenal glands. In the nerve terminals VIP is localize…

  17. 29.

    Onoue S, Misaka S, Yamada S · Naunyn-Schmiedeberg's archives of pharmacology · 2008 · PMID 18172612

    Vasoactive intestinal peptide (VIP) has been identified as one of major peptide transmitters in the central and peripheral nervous systems, being involved in a wide range of biological functions. The general physiologic effects of VIP include vasodilation, anti-inflammatory actions, cell proliferation, hormonal secretion, regulation of gastric motility, and smooth muscle relaxation; therefore, VIP has emerged as a promising drug candidate for the treatment of several diseases. A number of clinic…

  18. 30.

    Zudenigo D, Lacković Z · Lijecnicki vjesnik · 1989 · PMID 2576679

    A review of current advances in anatomy, physiology and pharmacology of vasoactive intestinal polypeptide (VIP) is presented. VIP is a basic 28-aminoacid peptide of molecular weight 3300. Nerves immunoreactive to VIP are in the heart, lung, digestive and genitourinary tract, eye, skin, ovaries and thyroid gland. In the central nervous system VIP-ergic neurons are found primarily in telencephalic areas. Here, VIP provokes the excitation, vasodilatation and together with noradrenaline participates…

  19. 31.

    Nagai K · Nihon yakurigaku zasshi. Folia pharmacologica Japonica · 2004 · PMID 15056940

    The hypothalamic suprachiasmatic nucleus (SCN), a master circadian oscillator in mammals, contains VIP-neurons. In our study on the mechanism of the central regulation of glucose metabolism in rats, we obtained following results: 1) intracranial injection of either 2-deoxy-D-glucose (2DG) or VIP elicited hyperglycemia by enhancing neural activities of the sympathetic nerves and by the suppression of the insulin secretion and enhances of secretions of adrenaline and glucagon; 2) bilateral lesions…

  20. 32.

    Weick RF, Stobie KM · Neuroscience and biobehavioral reviews · 1995 · PMID 7630581

    Vasoactive intestinal peptide (VIP) is found within neurons throughout the body. It influences the secretion of several hormones of the anterior pituitary by neural and pituitary actions. We review work from our laboratory that indicates that VIP inhibits the secretion of luteinizing hormone (LH) by a hypothalamic action. Experiments involving neural lesions indicate that VIP acts on the receptor field in the paraventricular nuclei of neurons whose cell bodies are located in the suprachiasmatic…

  21. 33.

    Smalley SG, Barrow PA, Foster N · Clinical and experimental immunology · 2009 · PMID 19604262

    Since the late 1970s a number of laboratories have studied the role of vasoactive intestinal peptide (VIP) in inflammation and immunity. These studies have highlighted the dramatic effect of VIP on immune cell activation and function, and studies using animal models of disease have indicated that VIP has significant therapeutic and prophylactic potential. This review will focus on the effects of VIP on innate immune cell function and discuss the therapeutic potential for VIP in inflammatory dise…

Research Articles

122
  1. 34.

    Chanchalani G · Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2025 · PMID 41368453

  2. 35.

    Igarashi H, Ito T, Mantey SA, Pradhan TK, et al. · The Journal of pharmacology and experimental therapeutics · 2005 · PMID 15994369

    Vasoactive intestinal peptide (VIP) is a widespread neurotransmitter whose physiological and pathophysiological actions are mediated by two receptor classes, VIP/pituitary adenylate cyclase-activating polypeptide (VPAC) 1 and VPAC2. VIP is a 28-amino acid peptide that is rapidly degraded and simplified; metabolically stable analogs are needed. In this study, we use information from studies of the VIP pharmacophore for VPAC1/VPAC2 to design nine simplified VIP analogs that could have high affinit…

  3. 36.

    Leuchte HH, Baezner C, Baumgartner RA, Bevec D, et al. · The European respiratory journal · 2008 · PMID 18978135

    Pulmonary hypertension (PH) leads to an increased right ventricular workload, cardiac failure and death. In idiopathic pulmonary arterial hypertension (PAH) the vasodilating vasoactive intestinal peptide (aviptadil) is deficient. The aim of the present study was to test the acute effects on haemodynamics and blood gases, and the safety, of a single dose of inhaled aviptadil in chronic PH. A total of 20 patients with PH (PAH in nine, PH in lung disease in eight and chronic thromboembolic PH in th…

  4. 37.

    Chen J, Xu H, Yang L, Chen F, et al. · Pediatric surgery international · 2025 · PMID 41342973

    To investigate vasoactive intestinal peptide (VIP) expression and distribution in fetal Sprague-Dawley (SD) rat lung with congenital diaphragmatic hernia (CDH). Assess the impact of VIP analog Aviptadil on CDH-associated lung hypoplasia. CDH was induced in pregnant SD rats by nitrofen gavage on E9.5. The CDH + VIP group received Aviptadil via tail vein from E10.5. Lung development was assessed by hematoxylin and eosin (HE) staining. VIP, α-SMA, and CD31 were evaluated by immunofluorescence (IF).…

  5. 38.

    Castagnola L, Gallino L, Schafir A, Vota D, et al. · Molecular and cellular endocrinology · 2025 · PMID 39894337

    Ovarian aging is associated with fibro-inflammation, contributing to the decline in oocyte count and quality. Given the immunomodulatory properties of the vasoactive intestinal peptide (VIP) in the reproductive tract, we investigated its role in maintaining ovarian immune homeostasis and preventing premature aging. We evaluated young VIP knockout (KO) mice, comparing them to young wild type (WT) females, for signs of premature aging. Histological staining revealed aberrant ovarian morphology in…

  6. 39.

    Al-Mitwalli A, Holden F, Di Giovanni A, Gobbo A, et al. · The journal of sexual medicine · 2025 · PMID 40192471

    Intracavernosal injection (ICI), most commonly with alprostadil, is recommended for Phosphodiesterase 5 Inhibitors (PDE5i) nonresponders in erectile dysfunction (ED) treatment; however, its use can cause pain (12%) and priapism (1%). We aimed to evaluate the efficacy of another ICI, Invicorp, and a combination of aviptadil with phentolamine mesylate (AvP), in contemporary practice. We conducted a retrospective single-center analysis on patients referred for AvP because they developed intolerable…

  7. 40.

    Sampley S, Bhasin D, Sekhri K, Singh H, et al. · Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2024 · PMID 38510776

    Dealing with life-threatening viral acute respiratory distress syndrome (ARDS) has always been challenging and with the recent COVID pandemic experience, there is still the need of newer therapies to alleviate mortality. Aviptadil, has shown significant beneficial results in covid. We share our experience with this molecule by doing a retrospective study to evaluate the effect of this drug on clinical outcomes in viral-related Ards patients. In this study, all patients with severe viral-related…

  8. 41.

    Deligianni C, Pellesi L, Chaudhry BA, Haulund Vollesen AL, et al. · Frontiers in neurology · 2023 · PMID 37143998

    Pituitary adenylate cyclase-activating peptide (PACAP) and vasoactive intestinal peptide (VIP) provoked cluster headache attacks in individuals with episodic cluster headache during their active phase and individuals with chronic cluster headache. In this study, we investigated whether infusions of PACAP and VIP caused alterations in plasma levels of VIP and their potential contribution to induced cluster headache attacks. Participants received either PACAP or VIP infusion for 20 min on 2 separa…

  9. 42.

    Vora A, Mehta P, Arora VK, Behera D, et al. · The Indian journal of tuberculosis · 2023 · PMID 37968060

  10. 43.

    Gross PC, Burkart SC, Müller R · Journal of pharmaceutical and biomedical analysis · 2014 · PMID 24176753

    Purification and quality control of therapeutic peptides is often performed by one single method, RP-HPLC. As usage of an orthogonal technique is highly advisable for quality assurance, capillary electrophoresis (CE) employing a coated capillary coupled via a sheathless interface to a mass spectrometer was applied in parallel. The basic therapeutic peptide aviptadil served as a model substance to study the impurity profiles revealing 15 detectable impurities using CE-MS, two were detected by an…

  11. 44.

    Foster N · Endocrine, metabolic & immune disorders drug targets · 2012 · PMID 23094826

    Numerous studies, since the late 1970s, have highlighted the role of vasoactive intestinal peptide (VIP) in the immune system of mammals. Importantly, these studies have show that VIP has an inhibitory effect on the production and action of many different inflammatory mediators and many studies have now shown the therapeutic potential of VIP in animal models of human disease. This review will briefly discuss the effects of VIP on immune cell function and discuss the therapeutic potential for VIP…

  12. 45.

    Mahmoudzadeh K, Habibi Z, Yousefi M, Mostafavi M, et al. · International journal of biological macromolecules · 2023 · PMID 37774815

    Increasing attention to peptides as prospective therapeutics has created a renaissance in searching for new alternatives to the current peptide synthetic approaches as well as their modification. In this context, it is necessary to develop different approaches for peptide ligation. Using enzymes as a novel strategy and powerful tool for the peptide and protein ligation has recently received a lot of attention. We here designed a fully convergent chemo-enzymatic peptide synthesis (CEPS) process f…

  13. 46.

    Mazuski C, Chen SP, Herzog ED · Journal of biological rhythms · 2020 · PMID 32536240

    The suprachiasmatic nucleus (SCN) drives circadian rhythms in locomotion through coupled, single-cell oscillations. Global genetic deletion of the neuropeptide

  14. 47.

    Mohney RP, Zigmond RE · The Journal of neuroscience : the official journal of the Society for Neuroscience · 1998 · PMID 9651211

    Neurons in the adult rat superior cervical sympathetic ganglion (SCG) dramatically increase their content of vasoactive intestinal peptide (VIP) and its mRNA after axotomy in vivo and after explantation. Because the VIP gene contains a functional cAMP response element, the effects of cAMP-elevating agents on VIP expression were examined. VIP, forskolin, or isoproterenol increased cAMP accumulation in explanted ganglia. Secretin, a peptide chemically related to VIP, or forskolin increased VIP lev…

  15. 48.

    Joye DAM, Rohr KE, Keller D, Inda T, et al. · Journal of biological rhythms · 2020 · PMID 32460660

    Circadian rhythms are programmed by the suprachiasmatic nucleus (SCN), which relies on neuropeptide signaling to maintain daily timekeeping. Vasoactive intestinal polypeptide (VIP) is critical for SCN function, but the precise role of VIP neurons in SCN circuits is not fully established. To interrogate their contribution to SCN circuits, VIP neurons can be manipulated specifically using the DNA-editing enzyme Cre recombinase. Although the Cre transgene is assumed to be inert by itself, we find t…

  16. 49.

    Li M, Xue Y, Chi L, Jin L · Current protein & peptide science · 2024 · PMID 38284716

    It has been proven that vasoactive intestinal peptide (VIP) was involved in the pathogenesis of prostate cancer. Cardin A variety of experiments were designed to study the binding process and structure-activity relationship between heparin oligosaccharides and VIP. Heparin was enzymatically digested and purified to produce heparin oligosaccharides, and the structures were characterized by NMR. The binding capacity between heparin oligosaccharides and VIP was analyzed by GMSA and ITC experiments.…

  17. 50.

    Sundler F, Alumets J, Håkanson R, Ingemansson S, et al. · Gastroenterology · 1977 · PMID 858483

    By immunohistochemistry, vasoactive intestinal polypeptide (VIP) was localized to nerve fibres and nerve cell bodies in the gallbladder wall of several mammals, including man. There is thus a morphological basis for accepting the powerful actions of VIP on gallbladder motility as physiological. VIP (vasoactive intestinal polypeptide), first thought of as a gut hormone, has recently been localized to a widely distributed system of nerves in the gut wall 1,2. In addition, nerves displaying VIP imm…

  18. 51.

    Yu R, Yang Y, Cui Z, Zheng L, et al. · Peptides · 2014 · PMID 25086267

    A novel peptide VIP-TAT with a cell penetrating peptide TAT at the C-terminus of VIP was constructed and prepared using intein mediated purification with an affinity chitin-binding tag (IMPACT) system to enhance the brain uptake efficiency for the medical application in central nervous system. It was found by labeling VIP-TAT and VIP with fluorescein isothiocyanate (FITC) that the extension with TAT increased the brain uptake efficiency of VIP-TAT significantly. Then short-term and long-term tre…

  19. 52.

    Merech F, Hauk V, Paparini D, Fernandez L, et al. · Biochimica et biophysica acta. Molecular basis of disease · 2021 · PMID 34186168

    Glucose uptake by the placenta and its transfer to the fetus is a finely regulated process required for placental and fetal development. Deficient placentation is associated with pregnancy complications such as fetal growth restriction (FGR). The vasoactive intestinal peptide (VIP) has embryotrophic effects in mice and regulates human cytotrophoblast metabolism and function. Here we compared glucose uptake and transplacental transport in vivo by VIP-deficient placentas from normal or VIP-deficie…

  20. 53.
  21. 54.

    Rao IH, Waller EK, Dhamsania RK, Chandrasekaran S · Cancers · 2023 · PMID 37444395

    VIP (vasoactive intestinal peptide) is a 28-amino acid peptide hormone expressed by cancer and the healthy nervous system, digestive tract, cardiovascular, and immune cell tissues. Many cancers express VIP and its surface receptors VPAC1 and VPAC2, but the role of autocrine VIP signaling in cancer as a targetable prognostic and predictive biomarker remains poorly understood. Therefore, we conducted an in silico gene expression analysis to study the mechanisms of autocrine VIP signaling in cancer…

  22. 55.

    Vu JP, Million M, Larauche M, Luong L, et al. · Journal of molecular neuroscience : MN · 2014 · PMID 24395090

    VIP is highly expressed in the colon and regulates motility, vasodilatation, and sphincter relaxation. However, its role in the development and progress of colitis is still controversial. Our aim was to determine the participation of VIP on dextran sodium sulfate (DSS)-induced colonic mucosal inflammation using VIP(-/-) and WT mice treated with VIP antagonists. Colitis was induced in 32 adult VIP(-/-) and 14 age-matched WT litter-mates by giving 2.5 % DSS in the drinking water. DSS-treated WT mi…

  23. 56.

    Fishbein VA, Coy DH, Hocart SJ, Jiang NY, et al. · Peptides · 1994 · PMID 7912431

    The ability to assess the importance of VIP in different physiological processes is limited by the lack of specific potent antagonists. In the present study, we have adopted two different approaches used successfully with other peptides in an attempt to identify new VIP receptor antagonists. One involves the formation of pseudopeptides by insertion of reduced peptide bonds in the NH2-terminus from position 2 to 8 of VIP. The other methodology involves the formation of a COOH-terminal chimeric an…

  24. 57.

    Henriksen JH, Staun-Olsen P, Fahrenkrug J, Ring-Larsen H · Scandinavian journal of gastroenterology · 1980 · PMID 7209387

    The concentration of vasoactive intestinal polypeptide (VIP) was determined in peripheral venous plasma from 136 patients with liver cirrhosis without gastrointestinal bleeding or coma and from 112 controls. In eight patients (cirrhosis, six; fibrosis, one; steatosis, one) arteriovenous extraction or release of VIP was measured during catheterization at four locations: brain, lower limb, intestine-liver, and kidney. The mean concentration of VIP in peripheral venous plasma from patients with cir…

  25. 58.

    Martins AB, Garnica-Siqueira MC, Zaia DAM, Zaia CTBV, et al. · Molecular and cellular biochemistry · 2018 · PMID 28752412

    Vasoactive intestinal peptide (VIP) is a neurotransmitter with anorectic effect that acts in the hypothalamus to regulate food intake. Oxytocin is a neuropeptide produced in the hypothalamus that controls energy homeostasis and has an inhibitory role on food intake. Thus, the present study aims at verifying the role of oxytocin as a mediator of VIP on energy homeostasis. For this purpose, intracerebroventricular microinjection of oxytocin receptor antagonist (vasotocin, OVT) or vehicle (NaCl 0.9…

  26. 59.

    Refai E, Jonsson C, Andersson M, Jacobsson H, et al. · Nuclear medicine and biology · 1999 · PMID 10708307

    Vasoactive intestinal peptide (VIP), a 28 amino-acid peptide was labeled with 131I and encapsulated into liposomes. 131I-VIP or liposomal 131I-VIP was administered intravenously into the rats. The distribution was studied by a gamma camera and established by counting the radioactivity in the removed organs. The elimination half-life for the liposomal 131I-VIP in both blood and lungs was significantly longer (5.29 and 9.28 min, respectively) than that obtained after the administration of 131I-VIP…

  27. 60.

    Li GH, Qian W, Song GQ, Hou XH · Journal of gastroenterology and hepatology · 2007 · PMID 17559364

    Vasoactive intestinal peptide (VIP) is a gastrointestinal hormone in the secretin-VIP family. It has been reported that VIP affects some tumor growth, and there is a VIP autocrine regulation in some cancers. However, the effect of VIP on gastric adenocarcinoma is not clear yet. The aim of the present study was to investigate the effect of VIP on gastric adenocarcinoma, especially autocrine regulation of VIP on gastric adenocarcinoma. VIP mRNA and protein, and its receptor mRNA (VIPR(1) and VIPR(…

  28. 61.

    Palmer JB, Cuss FM, Barnes PJ · Journal of applied physiology (Bethesda, Md. : 1985) · 1986 · PMID 3781947

    There is increasing evidence in many species that vasoactive intestinal peptide (VIP) may be a neurotransmitter in nonadrenergic inhibitory nerves. We have studied the effect of electrical field stimulation (EFS), exogenous VIP, and isoproterenol (Iso) on human airways in vitro. We have also studied a related peptide, peptide histidine methionine (PHM), which coexists with VIP in human airway nerves, and in separate experiments studied fragments of the VIP amino acid sequence (VIP1-10 and VIP16-…

  29. 62.

    Nanda C, Mehta C, Mehta Y, Joshi S, et al. · Journal of cardiothoracic and vascular anesthesia · 2024 · PMID 38458826

  30. 63.

    Moody TW, Mantey SA, Fuselier JA, Coy DH, et al. · Peptides · 2007 · PMID 17580098

    The effects of vasoactive intestinal peptide-camptothecin (VIP-CPT) conjugates were investigated on breast cancer cells and cells transfected with VIP receptors (R). (Ala(2,8,9,19,24.25.27), Nle(17), Lys(28))VIP, (A-NL-K)VIP, was synthesized and Lys(28) was coupled to a linker, N-methyl-amino-ethyl-glycine, L2, which formed a carbamate bond with CPT. The resulting (A-NL-K)VIP-L2-CPT was cytotoxic for MCF7 breast cancer cells, which have VPAC(1)-R, with IC(50) values of 380 and 90 nM using the MT…

  31. 64.

    Baraniuk JN, Lundgren JD, Okayama M, Mullol J, et al. · The Journal of clinical investigation · 1990 · PMID 2203825

    Vasoactive intestinal peptide (VIP), which is present with acetylcholine in parasympathetic nerve fibers, may have important regulatory functions in mucous membranes. The potential roles for VIP in human nasal mucosa were studied using an integrated approach. The VIP content of human nasal mucosa was determined to be 2.84 +/- 0.47 pmol/g wet weight (n = 8) by RIA. VIP-immunoreactive nerve fibers were found to be most concentrated in submucosal glands adjacent to serous and mucous cells. 125I-VIP…

  32. 65.

    Pandol SJ, Dharmsathaphorn K, Schoeffield MS, Vale W, et al. · The American journal of physiology · 1986 · PMID 2421587

    From structure-activity relationship studies of rat growth hormone-releasing factor (rGFR) on the vasoactive intestinal peptide (VIP) receptor in an in vitro preparation of exocrine pancreas, we predicted that [4Cl-D-Phe6, Leu17]VIP would be a competitive antagonist for the action of VIP. Micromolar concentrations of synthetic [4Cl-D-Phe6, Leu17]VIP competitively antagonized VIP-stimulated amylase release in the pancreatic preparation and VIP-stimulated short-circuit current changes in a colonic…

  33. 66.

    Hu WP, Li JD, Colwell CS, Zhou QY · Sleep · 2011 · PMID 21203371

    Vasoactive intestinal polypeptide (VIP) has been implicated in sleep regulation as a promoter of rapid eye movement (REM) sleep. Previous work has shown that the amount of time spent in REM sleep is increased by intracerebroventricular administration of VIP, and reduced by treatment with VIP antagonists or antibodies against VIP. A variety of evidence suggests that VIP is critical for normal expression of circadian rhythmicity of diverse physiological and behavioral parameters. In the present st…

  34. 67.

    Giladi E, Hill JM, Dresner E, Stack CM, et al. · Journal of molecular neuroscience : MN · 2007 · PMID 17952637

    Vasoactive intestinal peptide (VIP) is an important mediator of development during the neural tube closure period of embryogenesis and may regulate, in part, the expression of activity-dependent neuroprotective protein (ADNP), which is essential for neural tube closure and embryogenesis. To evaluate the impact of VIP expression in vivo on ADNP and the related protein ADNP2 the current study examined gene expression in adult wild-type (VIP +/+) and VIP null (VIP -/-) offspring of VIP deficient mo…

  35. 68.

    Mathew RC, Cook GA, Blum AM, Metwali A, et al. · Journal of immunology (Baltimore, Md. : 1950) · 1992 · PMID 1588046

    In murine schistosomiasis, granulomas form around ova deposited in the liver and intestines of infected mice. The granulomas have eosinophils that produce vasoactive intestinal peptide (VIP) and T cells that display VIP receptors. IL-5 is a lymphokine important for the development and maturation of eosinophils. It seemed plausible that VIP, released from eosinophils, may interact with lymphocyte VIP receptors and modulate IL-5 production as part of a feedback regulatory circuit. Thus, we determi…

  36. 69.

    Maher E, Bachoo M, Elabbady AA, Polosa C, et al. · British journal of urology · 1996 · PMID 8800898

    To determine whether a defect in vasoactive intestinal peptide (VIP)-mediated vasodilatation underlies diabetic impotence. Rats treated with streptozotocin for 8 weeks developed diabetes, as shown by hyperglycaemia and glycosuria, and had significant impairment of sexual function, as determined by tests of sexual behavior. The VIP content of the penis and major pelvic ganglion, the VIP release by the penis in vitro and the responsiveness of the vasculature of the penis in vivo to intracavernous…

  37. 70.

    Fernandez-Montesinos R, Castillo PM, Klippstein R, Gonzalez-Rey E, et al. · Nanomedicine (London, England) · 2009 · PMID 19958228

    We characterized a method to conjugate functional silver nanoparticles with vasoactive intestinal peptide (VIP), which could be used as a working model for further tailor-made applications based on VIP surface functionality. Despite sustained interest in the therapeutic applications of VIP, and the fact that its drugability could be largely improved by the attachament to functionalized metal nanoparticles, no methods have been described so far to obtain them. VIP was conjugated to tiopronin-capp…

  38. 71.

    Lajavardi L, Bochot A, Camelo S, Goldenberg B, et al. · Investigative ophthalmology & visual science · 2007 · PMID 17591893

    To reestablish the immunosuppressive microenvironment of the eye, disrupted by ocular inflammation during endotoxin-induced uveitis (EIU), by means of intravitreal injection of vasoactive intestinal peptide (VIP) in saline or encapsulated in liposomes, to increase its bioavailability and efficiency. EIU was induced in Lewis rats by subcutaneous injection of lipopolysaccharide (LPS). Simultaneously, animals were intravitreally injected with saline, saline/VIP, VIP-loaded liposomes (VIP-Lip), or u…

  39. 72.

    Ou X, Tan T, He L, Li Y, et al. · Cancer gene therapy · 2005 · PMID 15578065

    A 15-mer phosphorothioate antisense oligonuclide (ASON) complementary to the translation start region of the C-myc oncogene mRNA was radioiodinated to enhance its antitumor activity, and vasoactive intestinal peptide bound covalently polylysine (VIP-polylysine) was used as a carrier to deliver the oligonucleotide into VIP receptor-positive tumor cells. The antitumor activity of radioiodinated ASON conjugated to VIP-polylysine(VIP-131I-ASON) was investigated in athymic mice bearing HT29 tumor xen…

  40. 73.

    Zhang Z, Li Q, Huang Y, Xu Z, et al. · International journal of molecular sciences · 2022 · PMID 36499231

    Vasoactive intestinal peptide (VIP), a member of secretin/glucagon family, is involved in a variety of biological activities such as gut motility, immune responses, and carcinogenesis. In this study, the VIP precursor gene (

  41. 74.

    Robberecht P, Conlon TP, Gardner JD · The Journal of biological chemistry · 1976 · PMID 181379

    Secretin and vasoactive intestinal peptide (VIP), but not glucagon, stimulate accumulation of cyclic AMP in dispersed guinea pig pancreatic acinar cells. Secretin stimulated cellular accumulation of cyclic AMP by interacting with a single class of high affinity receptors. On the other hand, the dose-response curve for VIP-stimulated cellular cyclic AMP was biphasic and reflected interaction of this peptide with two classes of receptors. Results obtained with synthetic fragments of VIP and secret…

  42. 75.

    Horio B, Law NM, Rosenzweig SA · Investigative ophthalmology & visual science · 1995 · PMID 7529752

    To demonstrate a potential role for vasoactive intestinal peptide (VIP) in the regulation of ciliary process function, VIP receptors on rabbit ciliary process membranes were identified and characterized in biochemical and immunochemical studies. Membranes were isolated from rabbit ciliary processes, and VIP receptors were characterized by competition binding, affinity cross-linking, and N-glycanase digestion. A site-specific polyclonal antibody directed against the NH2-terminal end of the deduce…

  43. 76.

    Tan YV, Couvineau A, Lacapere JJ, Laburthe M · Annals of the New York Academy of Sciences · 2006 · PMID 16888228

    Site-directed mutagenesis and molecular modeling demonstrated that the N-terminal ectodomain of the VPAC1 receptor is a major site of vasoactive intestinal peptide (VIP) binding. Previous studies with the [Bpa6]-VIP and [Bpa22]-VIP probes (substitution with the photoactivable Bpa for the residues 6 and 22 in VIP) showed spatial approximation between the amino acids 6 and 22 of VIP and the 104-108 and 109-119 sequences within the N-terminal ectodomain of the receptor, respectively. Here, we chara…

  44. 77.

    Das DK, Kalfin R, Maulik N, Engelman RM · Annals of the New York Academy of Sciences · 1998 · PMID 9928024

    The present study sought to examine the interrelationship between nitric oxide (NO) and vasoactive intestinal peptide (VIP) in myocardial protection. Isolated rat hearts were perfused for 15 min with buffer only (Group I); 0.3 mM VIP (Group II); 3 mM L-arginine (a precursor of NO) (Group III); VIP and aminoguanidine (iNOS blocker) (Group IV); or L-arginine plus VIP 10-28 (VIP inhibitor) (Group V). Each heart was then made globally ischemic for 30 min followed by 2 h reperfusion. Both VIP and NO…

  45. 78.

    Grider JR, Makhlouf GM · The American journal of physiology · 1987 · PMID 3605338

    The role of vasoactive intestinal peptide (VIP) and its homologue, peptide histidine isoleucine (PHI), as neurotransmitters of inhibitory motor nerves of the gut, were examined in strips of guinea pig taenia coli and gastric fundic muscle. The stoichiometry of VIP release and muscle relaxation was determined in the presence and absence of the bee venom peptide, apamin, and the existence of prejunctional VIP/PHI receptors capable of regulating VIP/PHI release was explored. In both types of muscle…

  46. 79.

    Gozes Y, Brenneman DE, Fridkin M, Asofsky R, et al. · Brain research · 1991 · PMID 1647246

    Vasoactive intestinal peptide (VIP) is a neuropeptide which also interacts with cells of the immune system. The paucity of specific VIP receptor antagonists has hampered studies of possible receptor heterogeneity and of VIP function. To aid in achieving these goals, a new VIP antagonist, a hybrid between neurotensin and VIP, has been synthesized. This peptide interacted with VIP receptors on spinal cord cells with an affinity 10-fold greater than VIP itself. In contrast, 1000-fold higher concent…

  47. 80.

    Jovanovic S, Grbovic L, Jovanovic A · Molecular human reproduction · 2000 · PMID 10729319

    In order to provide sufficient nutrients for fetal development, pregnancy is associated with a significant increase in uterine blood flow. Although vasoactive intestinal polypeptide (VIP) is considered to be an important regulator of uterine blood flow it is not known whether endothelium-derived relaxing factors contribute to VIP action in the uterine artery, whether pregnancy alters the effect of VIP in the uterine artery and/or whether VIP interacts with noradrenaline and acetylcholine on the…

  48. 81.

    Sessler FM, Grady SM, Waterhouse BD, Moises HC · Peptides · 1991 · PMID 1788134

    Electrophysiological and biochemical studies suggest that VIP may exert a facilitating action in the neocortical local circuitry. In the present study, we examined the actions of VIP and VIP + norepinephrine (NE) on somatosensory cortical neuron responses to direct application of the putative transmitters acetylcholine (ACh) and gamma-aminobutyric acid (GABA). Spontaneous and transmitter-induced discharges of cortical neurons from halothane-anesthetized rats were monitored before, during and aft…

  49. 82.

    Hinson JP, Puddefoot JR, Kapas S · The Journal of endocrinology · 1999 · PMID 10194528

    Previous studies, by this group and others, have shown that vasoactive intestinal peptide (VIP) stimulates aldosterone secretion, and that the actions of VIP on aldosterone secretion by the rat adrenal cortex are blocked by beta adrenergic antagonists, suggesting that VIP may act by the local release of catecholamines. The present studies were designed to test this hypothesis further, by measuring catecholamine release by adrenal capsular tissue in response to VIP stimulation. Using intact capsu…

  50. 83.

    Kovacs CS, Chik CL, Li B, Karpinski E, et al. · The Journal of endocrinology · 1996 · PMID 8708540

    Pituitary adenylate cyclase-activating peptide (PACAP) and vasoactive intestinal peptide (VIP) share 68% homology and function as neurotransmitters or neuroendocrine factors. Although VIP immunoreactivity has been detected in bone cells, the presence of PACAP or PACAP receptors in bone has not been determined. In this study, we investigated the role of PACAP and VIP in regulating cAMP accumulation in the UMR 106 osteoblast-like tumor cell line. PACAP 27 (10(-9) to 3 x 10(-7) M), PACAP 38 (10(-9)…

  51. 84.

    Laburthe M, Couvineau A, Rouyer-Fessard C · Molecular pharmacology · 1986 · PMID 3003561

    In order to determine species specificity in growth hormone-releasing factor (GRF) interaction with vasoactive intestinal polypeptide (VIP) receptors, we have tested rat (r) GRF (with a His1 such as in VIP), human (h) GRF and position 1 substituted analogs of hGRF (Ala1, Ac-Tyr1, His1, Phe1, and Trp1 in the place of Tyr1) for their ability to inhibit 125I-VIP binding and to stimulate adenylate cyclase activity in human and rat intestinal epithelial membranes. We show that rGRF has a much higher…

  52. 85.

    Hermanstyne TO, Simms CL, Carrasquillo Y, Herzog ED, et al. · Journal of biological rhythms · 2016 · PMID 26712166

    The suprachiasmatic nucleus (SCN) regulates daily rhythms in physiology and behavior. Previous studies suggest a critical role for neurons expressing vasoactive intestinal peptide (VIP) in coordinating rhythmicity and synchronization in the SCN. Here we examined the firing properties of VIP-expressing SCN neurons in acute brain slices. Active and passive membrane properties were measured in VIP and in non-VIP neurons during the day and at night. Current-clamp recordings revealed that both VIP an…

  53. 86.

    Havel PJ, Dunning BE, Verchere CB, Baskin DG, et al. · Regulatory peptides · 1997 · PMID 9350974

    Vasoactive intestinal polypeptide (VIP) has been found in pancreatic nerves in several species. Studies were conducted to determine if VIP could be a parasympathetic neurotransmitter in the canine endocrine pancreas. To verify that VIP is localized in pancreatic parasympathetic nerves, sections of canine pancreas were immunostained for VIP. VIP staining was identified in the majority of neuronal cell bodies in intrapancreatic parasympathetic ganglia. In addition. VIP was localized in nerve fiber…

  54. 87.

    Zeng L, Zhang X, Xia M, Ye H, et al. · Biochimie · 2023 · PMID 37481062

    Vasoactive intestinal peptide (VIP) is a neuropeptide that play an important role in immunoregulation and anti-inflammation. Numerous inflammatory/autoimmune disorders are associated with decreased VIP binding ability to receptors and diminished VIP activation of cAMP generation in immune cells. However, the mechanisms linking oxidative/nitrative stress to VIP immune dysfunction remain unknown. It has been reported that the elevated heme or Cu

  55. 88.

    Lundberg P, Lundgren I, Mukohyama H, Lehenkari PP, et al. · Endocrinology · 2001 · PMID 11145597

    Three distinct complementary DNAs for vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) receptors have been cloned and designated VIP-1 receptor (VIP-1R), VIP-2 receptor (VIP-2R), and PACAP receptor (PACAP-R). In the present study, we have characterized the binding sites on primary mouse calvarial osteoblasts for VIP and related peptides. By analyzing the cAMP response, the rank order of response observed was PACAP 38 > PACAP 27 > helodermin > VIP > h…

  56. 89.

    Gao C, Lu X · Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2026 · PMID 40928995

  57. 90.

    Flood JF, Garland JS, Morley JE · Peptides · 1990 · PMID 2178250

    Vasoactive intestinal peptide (VIP) is a neuropeptide present in high concentrations in the hippocampus. The studies reported here demonstrate that VIP administered into the third ventricle of the brain caused amnesia in mice trained on a left-right footshock avoidance task in a T-maze. VIP resulted in amnesia when administered directly into the rostral portion of the hippocampus at a 10-fold lower dose than was needed to produce amnesia when VIP was administered intracerebroventricularly. When…

  58. 91.

    Akasu T, Gallagher JP, Hirai K, Shinnick-Gallagher P · The Journal of physiology · 1986 · PMID 3746700

    The effect of vasoactive intestinal polypeptide (VIP) on the neuronal membranes of isolated cat vesical pelvic ganglia and its underlying ionic mechanism were examined by means of intracellular recording and voltage-clamp techniques. Application of VIP (0.05-50 microM) to the neurones by pressure 'puff' ejection through a micropipette placed close to the neurones produced a depolarizing response (2-15 mV) in 83% of neurones tested; this effect was concentration dependent. The VIP-induced depolar…

  59. 92.

    Mazuski C, Abel JH, Chen SP, Hermanstyne TO, et al. · Neuron · 2018 · PMID 30017392

    The mammalian suprachiasmatic nucleus (SCN) functions as a master circadian pacemaker, integrating environmental input to align physiological and behavioral rhythms to local time cues. Approximately 10% of SCN neurons express vasoactive intestinal polypeptide (VIP); however, it is unknown how firing activity of VIP neurons releases VIP to entrain circadian rhythms. To identify physiologically relevant firing patterns, we optically tagged VIP neurons and characterized spontaneous firing over 3 da…

  60. 93.

    Fahrenkrug J, Ottesen B, Palle C · Regulatory peptides · 1989 · PMID 2623188

    The aim of the present study was to elucidate the importance of the C-terminal amide group for the biological activity of vasoactive intestinal peptide (VIP). Two synthetic peptides lacking the amide group: VIP having a carboxyl group at the C-terminus and the intermediate biosynthetic precursor, glycine-extended VIP were compared with VIP itself regarding the ability to inhibit spontaneous activity in smooth muscle strips from rat stomach and human Fallopian tube. Both the glycine-extended VIP…

  61. 94.

    Esendagli D · Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2026 · PMID 40982414

  62. 95.

    Ibata Y, Tanaka M, Ichitani Y, Takahashi Y, et al. · Neuroreport · 1993 · PMID 8453048

    Synaptic interaction between VIP-like immunoreactive (VIP-LI) and vasopressin-like immunoreactive (VASO-LI) neurones both of which are main neuronal components in the SCN was investigated using double labelling immunoelectron microscopy. VIP-LI axons were identified as having synaptic contacts with VASO-LI neuronal perikarya and dendrites. VIP-LI axons also formed synapses on non-immunoreactive dendrites or dendritic spines. In addition to the above findings, VIP-LI neuronal elements also formed…

  63. 96.

    Tiaho F, Nerbonne JM · Pflugers Archiv : European journal of physiology · 1996 · PMID 8772132

    Vasoactive intestinal peptide (VIP) is colocalized in parasympathetic nerve terminals in the heart and coreleased from these nerve terminals with the "classical" neurotransmitter acetylcholine (Ach). VIP also exerts a positive inotropic effect on the intact heart and enhances adenylyl cyclase activity in isolated heart membranes. Using the whole-cell patch-clamp technique, we show here that VIP enhances Ca2+ and Ba2+ currents (IBa) through voltage-dependent L-type Ca2+ channels in adult rat vent…

  64. 97.

    Charles EJ, Shaikh FA, Nemeth ZH · Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2026 · PMID 40675136

  65. 98.

    Hassan M, Refai E, Andersson M, Schnell PO, et al. · Nuclear medicine and biology · 1994 · PMID 9234336

    The in vivo distribution of vasoactive intestinal peptide (VIP) was studied for the first time using a rat model in combination with labeled VIP (131I-VIP) and a gamma-camera. A dynamic scan showed that 131I-VIP was cleared rapidly from the blood circulation. The radioactivity was taken up and accumulated in the lungs during the first minute. During the next 15 min, the radioactivity was slowly removed from the lungs and redistributed into the kidneys, gastric mucosa, liver and small intestine.…

  66. 99.

    Gozes I, Shani Y, Rostène WH · Brain research · 1987 · PMID 2441796

    Vasoactive intestinal peptide (VIP) is a major regulatory peptide in the nervous system, playing a role in normal brain activity. VIP levels change dramatically during postnatal rat brain development, raising the question of how these changes are regulated. To study VIP-gene expression, a sensitive RNA detection assay which uses in vitro-transcribed RNA hybridization probes, corresponding to 4 exons of the VIP-gene, was adapted. Results show that the major VIP-mRNA was 2000-2100 bases long in th…

  67. 100.

    Baecker B, Yanaihara N, Forssmann WG · Anatomy and embryology · 1983 · PMID 6351668

    An immunohistochemical study was carried out in order to investigate the occurrence of vasoactive intestinal polypeptide (VIP) in intralingual nervous tissue of different species. The study revealed that VIP-immunoreactive (IR) nerves and ganglia were widely found in all species studied. The following areas of the tongue tissue contain VIP-IR nerves: (1) Within the perivascular plexus many VIP-IR nerves can be found adjoining AV-anastomoses and medium-sized arteries, whereas the veins exhibit on…

  68. 101.

    Wernig K, Griesbacher M, Andreae F, Hajos F, et al. · Journal of controlled release : official journal of the Controlled Release Society · 2008 · PMID 18601963

    Drug delivery of protein and peptide-based drugs, which represent a growing and important therapeutic class, is hampered by these drugs' very short half-lives. High susceptibility towards enzymatic degradation necessitates frequent drug administration followed by poor adherence to therapy. Among these drugs is vasoactive intestinal peptide (VIP), a potent systemic and pulmonary vasodilator, which is a promising drug for the treatment of idiopathic pulmonary arterial hypertension (IPAH). Encapsul…

  69. 102.

    Moody TW, Zia F, Draoui M, Brenneman DE, et al. · Proceedings of the National Academy of Sciences of the United States of America · 1993 · PMID 8389448

    The most prevalent lung cancer, non-small cell lung cancer (NSCLC) has receptors for vasoactive intestinal peptide (VIP). Here the effects of a VIP antagonist (VIP-hyb) on NSCLC growth were investigated. In vivo, when VIPhyb (10 micrograms, s.c.) was daily injected into nude mice, xenograft formation was significantly inhibited by approximately 80%. In vitro, VIP (100 nM) stimulated colony formation approximately 2-fold, whereas 1 microM VIPhyb inhibited colony formation by approximately 50% whe…

  70. 103.

    O'Dorisio MS, Fleshman DJ, Qualman SJ, O'Dorisio TM · Regulatory peptides · 1992 · PMID 1313595

    Neuroblastoma is the most common solid tumor of children less than 5 years of age; yet the biology of this tumor is poorly understood. Neuroblastoma tumors are derived from neural crest precursors; they synthesize both adrenergic and peptidergic neurotransmitters. This study determined VIP receptor expression in primary neuroblastoma tumors prior to chemotherapy. The VIP receptor was expressed in 12 of 15 neuroblastoma tumors as determined by direct binding studies (KD = 1.3-12.4 nM) and VIP-med…

  71. 104.

    Cochaud S, Chevrier L, Meunier AC, Brillet T, et al. · Neuropeptides · 2010 · PMID 20638719

    Glioblastoma multiforme (GBM) is the most aggressive form of brain tumor in adults. This cancer has an infiltrative nature and the median survival of patients is about one year. Vasoactive intestinal peptide (VIP) belongs to a structurally related family of polypeptides and is a major regulatory factor in the central and peripheral nervous systems. VIP regulates proliferation of astrocytes and of numerous cancer cell lines and modulates migration in prostatic and colonic cancer cell lines. Littl…

  72. 105.

    Van Valen F, Jürgens H, Winkelmann W, Keck E · Cellular signalling · 1989 · PMID 2561912

    This study describes functional characteristics of receptors for vasoactive intestinal peptide (VIP) on human Ewing's sarcoma WE-68 cells. These characteristics include 125I-VIP binding capacity, cellular cAMP generation, glycogen hydrolysis, and pharmacological specificity. Binding studies with 125I-VIP showed specific, saturable, binding sites for VIP in WE-68 cells. Scatchard analysis revealed the presence of a single class of high-affinity binding sites that exhibited a dissociation constant…

  73. 106.

    Studeny S, Cheppudira BP, Meyers S, Balestreire EM, et al. · Journal of molecular neuroscience : MN · 2008 · PMID 18561033

    Vasoactive intestinal polypeptide (VIP) is an immunomodulatory neuropeptide widely distributed in neural pathways that regulate micturition. VIP is also an endogenous anti-inflammatory agent that has been suggested for the development of therapies for inflammatory disorders. In the present study, we examined urinary bladder function and hindpaw and pelvic sensitivity in VIP(-/-) and littermate wildtype (WT) controls. We demonstrated increased bladder mass and fewer but larger urine spots on filt…

  74. 107.

    Zhou ZC, Gardner JD, Jensen RT · Peptides · 1987 · PMID 2819833

    We investigated the abilities of VIP and secretin to occupy receptors and to increase cellular cyclic AMP using dispersed acini from guinea pig pancreas. The dose-inhibition curve for inhibition of binding of 125I-VIP by VIP was broad with detectable inhibition at 0.1 nM VIP, half-maximal inhibition at 2 nM VIP and complete inhibition at 10 microM VIP. Secretin also inhibited binding of 125I-VIP was compatible with two VIP-preferring receptors with one class having a high affinity for VIP (Kd 1.…

  75. 108.

    Rubinstein I, Ashok B, Tsueshita T, Onyüksel H · Peptides · 2005 · PMID 15652658

    The purpose of this study was to determine whether all D-vasoactive intestinal peptide (VIP), an inactive optical isomer of L-VIP, modulates the vasorelaxant effects of human L-VIP and pituitary adenylate cyclase activating peptide (PACAP)1-38, two ubiquitous and pleiotropic neuropeptides that activate VPAC1 and VPAC2, two VIP subtype receptors, in the intact peripheral microcirculation. Using intravital microscopy, we found that suffusion of all D-VIP had no significant effects on arteriolar di…

  76. 109.

    Reed HE, Meyer-Spasche A, Cutler DJ, Coen CW, et al. · The European journal of neuroscience · 2001 · PMID 11207820

    In mammals, the principal circadian pacemaker is housed in the hypothalamic suprachiasmatic nuclei (SCN). The SCN exhibit high levels of vasoactive intestinal polypeptide (VIP) immunoreactivity and two of the three VIP receptors, VPAC(2) and PAC(1), are found in the rat SCN. However, the role of VIP in the SCN remains unclear. In this study, we examined the phase-resetting actions of VIP and selective VIP receptor agonists on the electrical activity rhythm of rat SCN neurons in vitro. Applicatio…

  77. 110.

    Gozes I, McCune SK, Jacobson L, Warren D, et al. · The Journal of pharmacology and experimental therapeutics · 1991 · PMID 1646331

    A vasoactive intestinal peptide (VIP) antagonist was synthesized and used to investigate the interactions of VIP with its receptors present in the central nervous system (CNS). The VIP antagonist is a hybrid peptide consisting of a portion of VIP and a portion of neurotensin, designed to change the membrane permeability of the VIP portion. The hybrid antagonist displaced 80 to 90% of [125I]VIP binding to cell cultures from cerebral cortex, hippocampus or spinal cord. The displacement curve was b…

  78. 111.

    Alexander LD, Sander LD · Regulatory peptides · 1995 · PMID 8577937

    Previous studies in our laboratory have demonstrated that PVN administration of equimolar doses of VIP and PHI induce similar increases in plasma ACTH and CORT concentrations via the release of CRF and vasopressin in fasted, freely moving rats studied during the early light cycle. The purpose of these investigations was to determine whether VIP and PHI act via the same receptor and/or mechanism. Individual studies involving the PVN administration of either VIP or PHI in doses ranging from 0.3 to…

  79. 112.

    Robberecht P, De Neef P, Gourlet P, Cauvin A, et al. · Regulatory peptides · 1989 · PMID 2552509

    [Acetyl-His1]VIP stimulated adenylate cyclase with higher potency than VIP in membranes from human SUP-T1 lymphoblasts and was used as an efficient radioiodinated ligand with low non-specific binding to evaluate the relationship between receptor occupancy and adenylate cyclase activation and the possible interference of peptide T (an epitope derived from HIV envelope protein gp120). Various peptides inhibited [125I-acetyl-His1]VIP binding and activated the enzyme, their order of potency being: h…

  80. 113.

    Skobowiat C, Gonkowski S, Janiuk I, Całka J, et al. · Polish journal of veterinary sciences · 2009 · PMID 19886256

    The vasoactive intestinal peptide (VIP) and opioid family member Leu5-enkephalin (LENK) have already been established as playing independently significant roles in the functioning of the female genital tract. However, the mutual influence of both neuropeptides on female genital function has not been examined until now. Therefore, the aim of this study was to compare the distribution of VIP- and/or LENK-immunoreactive (IR) structures throughout the female genital tract of the pig. Immunohistochem…

  81. 114.

    Wollina U, Knopf B · International journal of oncology · 1993 · PMID 21573541

    Vasoactive intestinal peptide (VIP) has been shown to affect the proliferative activity of human keratinocytes in vitro. In our present study, we investigated whether VIP affects early events of keratinocyte migration, i.e. the formation of pseudopodia-like protrusions and the zeta-potential which was assessed by the electrophoretic mobility (EM). Under optimal culture conditions (10% fetal calf serum supplement; FCS) VIP changed the total percentage of migrating HaCaT cells by increasing the Ki…

  82. 115.

    Miyata A, Jiang L, Stibbs HH, Arimura A · Regulatory peptides · 1992 · PMID 1574609

    Two forms of pituitary adenylate cyclase activating polypeptides with 38 (PACAP38) and 27 residues (PACAP27) respectively were recently isolated from ovine hypothalamic tissues. The N-terminal 28 amino acids sequence of PACAP was found to have 68% homology with porcine vasoactive intestinal peptide (VIP). In order to determine whether the primary structure of VIP of ovine hypothalamus is identical with porcine VIP or similar to PACAP, VIP immunoreactivity as determined by radioimmunoassay for po…

  83. 116.

    Weinstock JV, Blum AM, Khetarpal S · Cellular immunology · 1991 · PMID 1673641

    Granulomas develop around schistosome ova in murine Schistosoma mansoni. These granulomas have eosinophils that produce VIP. It is possible that VIP participates in immunoregulation. VIP-mediated effects usually operate through a cAMP-dependent mechanism. To identify VIP-responsive inflammatory cells in murine schistosomiasis, inflammatory cells were exposed to VIP and assessed for adenylate cyclase activation and VIP binding. VIP increased adenylate cyclase activity in splenic lymphocytes from…

  84. 117.

    Esendagli D · Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2026 · PMID 40652932

  85. 118.

    Ekblad E, Alumets J, Ekman R, Falkmer S, et al. · Peptides · 1985 · PMID 3913914

    In the ray gut immunoreactive VIP has a dual localization in endocrine cells and in nerve fibers. Immunoreactive VIP and PHI were found to co-exist in the same nerve fibers. This is predictable, since VIP and PHI derive from the same precursor. However, PHI could not be demonstrated in the VIP immunoreactive endocrine cells. Chromatographic analysis (high performance liquid chromatography) of extracts of the gut revealed two different molecular forms of VIP, one large peak with an elution positi…

  86. 119.

    Muller JM, Lolait SJ, Yu VC, Sadée W, et al. · The Journal of biological chemistry · 1989 · PMID 2537287

    Three phenotypically distinct subclones (SH-SY-5Y, SH-EP, SH-IN) of the human neuroblastoma cell line SK-N-SH were found to possess vasoactive intestinal polypeptide (VIP) precursor mRNA, release immunoreactive VIP, and express high-affinity VIP receptors coupled to adenylate cyclase. The apparent molecular mass for the receptor polypeptide, as determined by covalent cross-linking of 125I-VIP, was 49 kDa. After 2 days in culture, a concentration of immunoreactive VIP equivalent to the binding af…

  87. 120.

    Lee SS, Huang M, Ma Z, Rorstad O · Hepatology (Baltimore, Md.) · 1996 · PMID 8621151

    Vasoactive intestinal peptide (VIP) blood levels in cirrhosis are elevated, but its hemodynamic and receptor characteristics remain unclarified. We aimed to quantify VIP receptor characteristics in mesenteric arteries, plasma VIP concentration by radioimmunoassay (RIA), and the hemodynamic effects of VIP infusion in bile duct-ligated (BDL) cirrhotic and sham-operated control rats. Mesenteric arterial membranes were prepared by ultracentrifugation, and receptor characteristics were studied using…

  88. 121.

    Koh SW, Chandrasekara K, Abbondandolo CJ, Coll TJ, et al. · Investigative ophthalmology & visual science · 2008 · PMID 18441300

    Vasoactive intestinal peptide (VIP) is expressed by corneal endothelial (CE) cells and is present in the aqueous humor, which bathes CE cells in vivo. This study demonstrated the role of CE cell VIP in maintaining the expression level of a CE differentiation marker, N-cadherin, and the hexagonal cell shape. To determine the most effective VIP concentration, bovine corneoscleral explants were treated with 0 (control) and 10(-12) to 10(-6) M VIP. Paired human corneas (nine donors) from an eye bank…

  89. 122.

    Samarasinghe AE, Hoselton SA, Schuh JM · Regulatory peptides · 2010 · PMID 20566347

    Vasoactive intestinal peptide (VIP) is a neuropeptide with cytokine properties that is abundant in the lung. VIP null mice exhibit spontaneous airway inflammation and hyperresponsiveness emphasizing VIP's "anti-asthma" potential. Although VIP's impending protective role in the lung has been demonstrated, its localization in the naïve and allergic murine lungs has not. To this aim, we analyzed the availability of VIP and its protease, neutral peptidase (NEP), in naïve and Aspergillus-sensitized a…

  90. 123.

    Girard BM, Malley SE, Braas KM, Waschek JA, et al. · Journal of molecular neuroscience : MN · 2008 · PMID 18483878

    Vasoactive intestinal polypeptide (VIP) is an immunomodulatory neuropeptide distributed in micturition pathways. VIP(-/-) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide (CYP)-induced cystitis. Given VIP's role as an anti-inflammatory mediator, we hypothesized that VIP(-/-) mice would exhibit enhanced inflammatory mediator expression after cystitis. A mouse inflammatory cytokine and receptor RT2 profiler array was used to determin…

  91. 124.

    Gozes I · Journal of molecular neuroscience : MN · 2008 · PMID 18607776

    Vasoactive intestinal peptide (VIP) is an interesting example of a 28-amino acid neuropeptide that is abundantly expressed in discrete brain regions/neurons and hence may contribute to brain function. This short review summarizes my own point of view and encompasses 25 years of work and over 100 publications targeting the understanding of VIP production and biological activity. The review starts with our original cloning of the VIP gene, it then continues to discoveries of regulation of VIP synt…

  92. 125.

    Grunditz T, Ekman R, Håkanson R, Sundler F, et al. · Regulatory peptides · 1988 · PMID 3068708

    Neuropeptide Y (NPY) and vasoactive intestinal peptide (VIP) occur in nerve fibers around blood vessels and between follicles in the thyroid gland of the mouse and rat. VIP-immunoreactive fibers are numerous, while NPY-immunoreactive fibers are fewer. Most of the latter fibers contain noradrenaline (NA) as well as NPY, while a subpopulation was found to contain VIP instead of NA. We have determined the origins of rat thyroid nerve fibers containing NPY, VIP or NPY/VIP by investigating 3 conceiva…

  93. 126.

    De Beurme FA, Lefebvre RA · The Journal of pharmacy and pharmacology · 1988 · PMID 2907538

    Relaxations were induced in longitudinal muscle strips of the rat gastric fundus by stimulation of non-adrenergic non-cholinergic (NANC) neurons and by administration of vasoactive intestinal polypeptide (VIP) or isoprenaline. The effect of antiserum against vasoactive intestinal polypeptide (VIP antiserum) and of control serum on these relaxations was investigated. Incubation with VIP antiserum (dilution 1/50) for 1 h almost completely prevented the relaxation by VIP. It partially prevented the…

  94. 127.

    Villuendas G, Sánchez-Franco F, Palacios N, Fernández M, et al. · Brain research. Molecular brain research · 2001 · PMID 11597765

    Previous studies have shown that BDNF promotes expression of SS. In earlier studies we demonstrated the stimulatory effect of locally produced VIP upon SS secretion. These facts led us to explore the peptidergic action of BDNF on VIP, and to determine if BDNF-induced SS might be mediated by the induction of VIP. Cultured fetal rat cerebrocortical cells were incubated with BDNF (50 ng/ml) and/or VIP (10(-11) M) for 2 and 5 days. In other experiments IgGs from BDNF or VIP antisera were also added.…

  95. 128.

    Martin JM, Luis J, Marvaldi J, Pichon J, et al. · European journal of biochemistry · 1989 · PMID 2538331

    Vasoactive intestinal peptide (VIP) stimulated in a dose-dependent manner the accumulation of cAMP in human melanoma-derived cell line IGR39. The maximal effect (about 100 times the basal level) was observed with 10 nM VIP. Half-maximum cAMP production was obtained at 0.78 nM VIP. VIP-related peptides were also potent in stimulating the cAMP production in IGR39 cells. The order of potency was VIP much greater than peptide histidine-methioninamide greater than human growth-hormone-releasing facto…

  96. 129.

    Leiser J, Blum JJ · FEBS letters · 1984 · PMID 6540208

    The effects of vasoactive intestinal polypeptide (VIP) and of forskolin on alanine metabolism in hepatocytes isolated from fed and fasted rats were examined. VIP and 17 microM forskolin stimulated glucose production, gluconeogenesis from alanine, and ureagenesis, and inhibited glyconeogenesis to comparable degrees. However, combination of 17 microM forskolin with a maximal dose of VIP significantly augmented only the inhibition of glyconeogenesis. At 100 microM, forskolin induced metabolic respo…

  97. 130.

    Sidawy AN, Sayadi H, Harmon JW, Termanini B, et al. · The Journal of surgical research · 1989 · PMID 2547110

    Vasoactive intestinal peptide (VIP) is a widely distributed neurotransmitter whose dilatory effects on vascular smooth muscle are believed to be mediated via specific receptors. To determine the possible role of VIP in regulating specific vascular beds, we examined the relationship between arterial wall VIP content as determined by radioimmunoassay and VIP receptors mapped by autoradiography. Analysis of arteries from 12 adult New Zealand rabbits showed that VIP receptors were consistently locat…

  98. 131.

    Gozes I, Schächter P, Shani Y, Giladi E · Neuroendocrinology · 1988 · PMID 3340270

    Vasoactive intestinal peptide (VIP) gene transcripts were demonstrated by RNA blot hybridization using VIP-specific RNA hybridization probes. High levels of expression were observed as early as in 16-day-old embryos. In aging rats, the VIP-mRNA levels were reduced significantly (in the cerebral cortex) as compared to 21-day-old rats. Our results suggest a role for the VIP gene protein products during embryonal development. During aging processes the decrease in VIP gene transcripts may be a cons…

  99. 132.

    Gozes I, Lilling G, Glazer R, Ticher A, et al. · The Journal of pharmacology and experimental therapeutics · 1995 · PMID 7714762

    To distinguish vasoactive intestinal peptide (VIP) receptors in the brain-mediating neurotransmission and neurotrophism, potent VIP analogues were designed. Using a single amino acid substitution and the addition of a fatty acyl moiety, an analogue was devised that exhibited both a 100-fold greater potency than VIP and specificity for a VIP receptor associated with neuronal survival. This VIP agonist increased neuronal survival via a cAMP-independent mechanism. Identical chemical modification of…

  100. 133.

    Brandi ML, Rotella CM, Kohn LD, Toccafondi R · The Journal of clinical endocrinology and metabolism · 1986 · PMID 2871039

    When individually tested, vasoactive intestinal peptide (VIP), cholera toxin, and monoclonal thyroid-stimulating antibodies (TSAbs), but not TSH binding-inhibiting antibodies (TBIAbs), elevate cAMP levels in cultured human thyroid cells. In this study, we tested the effect on cAMP levels in human thyroid cells of the simultaneous presence of VIP and the other ligands noted. Monoclonal TBIAbs (11E8 and 122G3), which interact with a membrane glycoprotein containing the high affinity binding site o…

  101. 134.

    Lim MA, Stack CM, Cuasay K, Stone MM, et al. · International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience · 2008 · PMID 18423945

    Pharmacological studies indicate that vasoactive intestinal peptide (VIP) may be necessary for normal embryonic development in the mouse. For example, VIP antagonist treatment before embryonic day 11 resulted in developmental delays, growth restriction, modified adult brain chemistry and reduced social behavior. Here, developmental milestones, growth, and social behaviors of neonates of VIP-deficient mothers (VIP +/-) mated to VIP +/- males were compared with the offspring of wild type mothers (…

  102. 135.

    Dagar S, Sekosan M, Rubinstein I, Onyüksel H · Breast cancer research and treatment · 2001 · PMID 11245339

    Vasoactive intestinal peptide (VIP) is a 28 amino acid neuropeptide with a wide range of biological activities. Receptors for VIP (VIP-R) are overexpressed in breast cancer, where they may have diagnostic and therapeutic implications. Although N-methyl nitrosourea (MNU)-induced breast cancer in rats is used extensively as a model to study mammary carcinogenesis, there is no information about the expression of VIP-R in this model. Therefore, the purpose of this study was to investigate the presen…

  103. 136.

    Ikezaki H, Paul S, Alkan-Onyüksel H, Patel M, et al. · The American journal of physiology · 1998 · PMID 9688960

    The purpose of this study was to determine whether a monoclonal anti-vasoactive intestinal peptide (VIP) antibody, which binds VIP with high affinity and specificity and catalyzes cleavage of the peptide in vitro, attenuates VIP vasorelaxation in vivo and, if so, whether insertion of VIP on the surface of sterically stabilized liposomes (SSL), which protects the peptide from trypsin- and plasma-catalyzed cleavage in vitro, curtails this response. Using intravital microscopy, we found that suffus…

  104. 137.

    Pence JC, Shorter NA · Journal of pediatric surgery · 1992 · PMID 1328588

    Elevated serum levels of vasoactive intestinal peptide (VIP) are associated with some cases of neuroblastoma and correlate with a favorable prognosis. VIP has previously been shown in our laboratory to cause the in vitro growth inhibition and morphological differentiation of the human neuroblastoma cell line, LA-N-5. It is now shown that LA-N-5 cells express immunoreactive VIP and bear specific VIP receptors. Antagonism of endogenous VIP, either by competitive inhibition or receptor blockade, in…

  105. 138.

    Collado B, Carmena MJ, Sánchez-Chapado M, Ruíz-Villaespesa A, et al. · International journal of oncology · 2005 · PMID 15870879

    Vasoactive intestinal peptide (VIP) functions as a mitogenic agent in the human prostate gland acting by autocrine/paracrine mechanisms. Here we extend knowledge on the VIP system (expression of VIP and VIP receptors, functionality of VIP receptors) at this level by analyzing the differences between human normal prostate and prostate carcinoma specimens. RT-PCR showed the expression of mRNA for VIP in normal and malignant tissues, whereas VIP levels, as measured by enzyme immuno-analysis, were a…

  106. 139.

    Metwali A, Blum AM, Elliott DE, Weinstock JV · American journal of physiology. Gastrointestinal and liver physiology · 2002 · PMID 12065298

    In schistosomiasis, eggs induce granulomas that have a vasoactive intestinal peptide (VIP) immunoregulatory circuit. This study explored the regulation of VIP production at sites of inflammation. Splenocytes from uninfected C57BL/6 mice expressed VIP mRNA and protein, which stopped following egg deposition. Eggs induce a Th2 response, suggesting that Th2 cytokines like interleukin (IL)-4 can regulate VIP. To address this issue, splenocytes from uninfected mice were incubated for 4 h with or with…

  107. 140.

    Anderson FL, Kralios AC, Hershberger R, Bristow MR · The American journal of physiology · 1988 · PMID 2843056

    Desensitization to the hemodynamic effects of vasoactive intestinal polypeptide (VIP) was examined in 12 anesthetized, open-chest dogs in which cardiac output, systemic arterial resistance, and heart rate were fixed. VIP was administered by intracoronary infusion, and the effects were compared with isoproterenol and forskolin. Measurements of left ventricular maximum rate of pressure development (dP/dt), coronary blood flow, and myocardial oxygen consumption were made before and after a 90-min i…

  108. 141.

    Yusta B, Holland D, Waschek JA, Drucker DJ · Endocrinology · 2012 · PMID 22535770

    The enteroendocrine and enteric nervous systems convey signals through an overlapping network of regulatory peptides that act either as circulating hormones or as localized neurotransmitters within the gastrointestinal tract. Because recent studies invoke an important role for vasoactive intestinal peptide (VIP) as a downstream mediator of glucagon-like peptide-2 (GLP-2) action in the gut, we examined the importance of the VIP-GLP-2 interaction through analysis of Vip(-/-) mice. Unexpectedly, we…

  109. 142.

    Csaba Z, Csernus V, Gerendai I · Peptides · 1997 · PMID 9437717

    PACAP, VIP, anti-PACAP and anti-VIP antisera were injected intratesticularly. In 9-day-old hemicastrated rats PACAP or VIP decreased basal testosterone secretion. In 22-day-old hemicastrates VIP but not PACAP reduced compensatory testicular hypertrophy, however, neither PACAP nor VIP altered steroidogenesis. Anti-VIP antiserum to this age group increased testosterone production and enhanced compensatory testicular hypertrophy. In adult hemicastrates neither the peptides nor the antisera influenc…

  110. 143.

    Georg B, Fahrenkrug J · Brain research. Molecular brain research · 2000 · PMID 10925144

    In many ganglia, the neuropeptide pituitary adenylate cyclase-activating peptide (PACAP) innervates nerve cell bodies containing the homologous neuropeptide vasoactive intestinal polypeptide (VIP). We therefore investigated whether PACAP affected the VIP gene expression and elucidated the molecular mechanisms using the human neuroblastoma cell line NB-1. A concentration dependent induction of the VIP mRNA level was found upon PACAP stimulation. Five nM PACAP mediated transient elevation of the V…

  111. 144.

    Chougale S, Singh P, Surapaneni V, Chaudhry D. · 2024

  112. 145.

    Tiwari S, Yadav SK, Kumari M, Dhakal T, Puranik N. · 2026 · PMID 41977389

    Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by memory decline, cognitive impairment, and behavioral changes, ultimately leading to a loss of independence and reduced quality of life. Although understanding of the molecular basis of AD has advanced, effective disease-modifying therapies remain scarce. Neuropeptides are small protein-like signaling molecules that regulate diverse physiological processes, including mood, memory, and neuronal function. Growing…

  113. 146.

    Xu J, Wu G, Chen M, Chen G. · 2026 · PMID 42003223

    In nasopharyngeal carcinoma, mitochondria often function abnormally. However, the precise signals that cause excessive mitochondrial division are still undefined. Levels of the neuropeptide Vasoactive Intestinal Peptide are altered in NPC tissues. How VIP influences the metabolic behavior of cancer cells is not well established. Our experiments utilized established NPC cell lines. We tested how physiological concentrations (10-100 nM) of VIP exposure affect survival and mitochondrial integrity.…

  114. 147.

    You Y, Li Q, Yang X, Zou Y, Lu Q, Liao W, Wang H, Li Z, Wu X. · 2026 · PMID 42061597

    <h4>Purpose</h4>To investigate whether intravitreal vasoactive intestinal peptide (VIP) attenuates form-deprivation myopia (FDM) in a dose-dependent manner in guinea pigs and to determine whether this effect is mediated through regulation of the scleral Wnt/β-catenin signaling pathway.<h4>Methods</h4>A customized latex-balloon facemask was used to induce monocular FDM by covering the right eye, with the left eye remaining uncovered and serving as an internal self-control (SC). Fifty-four 3-week-…

  115. 148.

    Dawlaty R, Entsie P, Amoafo EB, Liverani E, Dorsam GP. · 2026 · PMID 42117802

    The neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) have emerged as potent modulators of immune responses during sepsis, yet their roles remain complex, alternating between protective and permissive depending on timing, tissue compartment, and inflammatory context. This review presents a historical assessment of VIP and PACAP in sepsis research, highlighting the evolution of conceptual advances across five decades. Starting in the…

  116. 149.

    Castro-Vázquez D, García-López I, Wirsig K, Arribas-Castaño P, Gomariz RP, Martínez C, Juarranz Y, Bernhardt A, Carrión M. · 2026 · PMID 42013997

    Bone remodelling is a dynamic process of osteoblastic bone formation and osteoclastic bone resorption, regulated by local, paracrine and endocrine factors, in which osteocytes act as orchestrators of bone homeostasis. Among these regulatory factors, the neuropeptide VIP (vasoactive intestinal peptide) has demonstrated osteoprotective effects by inhibiting osteoclastogenesis and promoting osteoblast differentiation. However, its potential role in osteocyte biology remains unexplored. In this stud…

  117. 150.

    Li L, Wang D, Zhang J, Xiao F, Shao C. · 2026 · PMID 41891524

    Renal cell carcinoma (RCC) is a common urologic malignancy with limited treatment options. The neuropeptide vasoactive intestinal peptide (VIP) regulates diverse biological processes by binding to VPAC1 and VPAC2 receptors, but its role in RCC remains unclear. The proliferation of RCC Caki-1 cells was evaluated using the Cell Counting Kit-8 (CCK-8), while lactate dehydrogenase (LDH) and γ-glutamyl transpeptidase (γ-GPT) release were measured using commercial kits. Reactive oxygen species (ROS) l…

  118. 151.

    Han K, Liao M, Zhang J, Zhong R, Mei L, Ju D, Zhang EE, Huang Y. · 2026 · PMID 41536242

    In mammals, the suprachiasmatic nucleus (SCN) functions as the primary driver of circadian rhythm. Although individual SCN neurons exhibit cell-autonomous oscillations, intercellular communication-mediated by neural peptides such as vasoactive intestinal polypeptide (VIP)-synchronizes their rhythms. However, the precise molecular mechanism by which VIP facilitates SCN synchronization remains elusive. Here, we introduce an automated ex vivo culture system, termed 'brain-slice-in-a-chamber' (BaSIC…

  119. 152.

    Anastasio C, Peduto L. · 2026 · PMID 41795422

    Intestinal homeostasis and regeneration rely on intestinal stem cells (ISCs). Li et al.<sup>1</sup> identified neuronal vasoactive intestinal peptide (VIP) as a brake on ISCs through VIPR1 to limit regeneration. In Nature Immunology, Jakob et al. and Pirzgalska et al. further showed that VIP-VIPR1 signaling restrains secretory lineage expansion and balances immune responses.<sup>2</sup><sup>,</sup><sup>3</sup>.

  120. 153.

    Wang M, Tsuno Y, Peng Y, Islam MT, Matsui A, Maejima T, Mieda M. · 2026 · PMID 41486279

    The central circadian clock of the suprachiasmatic nucleus (SCN) comprises a network of diverse neuronal and glial cell types, yet its operating mechanism remains elusive. Here, by monitoring cellular calcium rhythms in vivo using dual-color fiber photometry in mice lacking vasoactive intestinal polypeptide (VIP), we demonstrate that arginine vasopressin (AVP) neurons oscillate intrinsically with a short period and reduced amplitude. This indicates that VIP normally amplifies and phase-delays th…

  121. 154.

    Wang Y, Sen-Majumdar A, Li JM, Sarkar S, Passang T, Mecorapaj S, Balaji S, Kalsang T, Ward AB, Li Y, Cohen J, Chen Z, Chaudagar K, Das PK, Wang S, Bruk N, Papadantonakis N, Giver CR, Waller EK. · 2026 · PMID 41478571

    Vasoactive intestinal peptide (VIP) is a neuropeptide involved in cancer proliferation and immune suppression. The limited potency of the VIP antagonist peptide VIPhyb in T-cell activation and murine anti-leukemia models prompted the development of a more potent antagonist. We screened a combinatorial library of VIPhyb C-terminal peptide sequence variants to identify a higher-affinity VIP-receptor (VIP-R) antagonist, hypothesizing that specific amino acid substitutions could improve receptor bin…

  122. 155.

    Xiang J, Xu J, Zhu J, Yang B, et al. · Molecular therapy : the journal of the American Society of Gene Therapy · 2026 · PMID 42619264

    Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory tract disease in infants and older adults; however, vaccine strategies capable of inducing robust respiratory mucosal immunity remain limited. Here, we developed a receptor-guided intranasal circular RNA (circRNA) vaccine platform based on a vasoactive intestinal peptide-nucleocapsid fusion protein (VIP-N), which enables the self-assembled delivery of circRNA encoding RSV antigens. Mechanistically, VIP-N enters cells t…

Preprints (not yet peer-reviewed)

4
  1. 156.

    Chen J, Xu H, Yang L, Chen F, Li K, Xu B, Liu W, Hou F. · 2025

    <title>Abstract</title> <p>Purpose To investigate vasoactive intestinal peptide (VIP) expression and distribution in fetal rat lung with congenital diaphragmatic hernia (CDH). Assess the impact of VIP analog Aviptadil on CDH-associated lung hypoplasia. Methods CDH was induced in pregnant SD rats by nitrofen gavage on E9.5. The CDH + VIP group received Aviptadil via tail vein from E10.5. Lung development was assessed by hematoxylin and eosin (HE) staining. VIP, α-SMA, and CD31 were evaluated by i…

  2. 157.

    Puttapaka SN, Admasu IA, Scott A, Sonmez G, Seika P, Rajkumar M, Valencia X, Consorti A, Hong SM, Slosberg J, Fagiolini M, Kulkarni S. · 2026

    Gastrointestinal (GI) dysmotility is a highly prevalent and clinically significant feature of Rett syndrome (RTT), yet its underlying mechanisms remain poorly defined. Here, we investigated these mechanisms of GI dysmotility in a Mecp2-null mouse model of RTT. First, we observed that MeCP2 was expressed in murine myenteric ganglia, including in enteric neurons and that Mecp2-null males developed maturation-associated functional regression in their GI motility. In dysmotile mice, longitudinal mus…

  3. 158.

    Cabrera-Martín A, Arribas-Castaño P, Castro-Vázquez D, Tecza K, Pérez-García S, Martinez C, Khamlichi CE, Morisset-López S, Juarranz Y, Gutiérrez-Cañas I, Villanueva-Romero R. · 2026

    <title>Abstract</title> <p>Background Vasoactive Intestinal Peptide (VIP) is a pleiotropic neuropeptide regulating diverse cellular and physiological processes. Its functions are primarily mediated through two G protein–coupled receptors, VPAC1 and VPAC2. The aim of this study was to perform an integrative analysis of VPAC receptor signalling, encompassing receptor–G protein coupling, second messenger production, kinase activation and transcriptional responses in T cells. Experimental Approach :…

  4. 159.

    Boesing M, Abig K, Brändle M, Brutsche M, Burri E, Frye BC, Giezendanner S, Grutters JC, Haas P, Heisler J, Jaun F, Leuppi-Taegtmeyer AB, Lüthi-Corridori G, Müller-Quernheim J, Nüesch R, Pohl W, Rassouli F, Leuppi JD. · 2022

    <title>Abstract</title> <p><bold>Background</bold>: Despite the fast establishment of new therapeutic agents in the management of COVID-19 and large-scale vaccination campaigns since the beginning of the SARS-CoV-2 pandemic in early 2020, severe disesase-courses still represent a threat, especially to patients with risk factors. This indicates the need for alternative strategies to prevent respiratory complications like acute respiratory distress system (ARDS) associated with COVID-19. Aviptadil…

Case Reports

2
  1. 160.

    Youssef JG, Bitar MZ, Zahiruddin F, Al-Saadi M, et al. · Critical care explorations · 2022 · PMID 35018346

    Aviptadil, a synthetic form of human vasoactive intestinal peptide, has entered clinical trials to treat critical coronavirus disease 2019 pneumonia with respiratory failure. Vasoactive intestinal peptide protects the lung against a broad array of injuries by binding to the vasoactive intestinal peptide receptor 1 receptor of alveolar type II cells, the cells that severe acute respiratory syndrome coronavirus 2 binds to. As the role of Aviptadil in treating pregnant patients with critical corona…

  2. 161.

    Mehta Y, Mehta C, Chandrasekaran A · Respiratory medicine case reports · 2024 · PMID 38370871

    Acute Respiratory Distress Syndrome (ARDS) is a severe and potentially life-threatening lung condition that often leads to Intensive Care Unit (ICU) admissions. Treating ARDS in the ICU involves providing essential support for proper oxygenation and ventilation, often requiring mechanical ventilation using high positive end-expiratory pressure (PEEP) to recruit alveoli. Strategies like prone positioning and extracorporeal membrane oxygenation (ECMO) may be necessary for stubbornly low oxygen lev…

Curated sources on file

19
  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.
  9. 9.
  10. 10.
  11. 11.
  12. 12.
  13. 13.
  14. 14.
  15. 15.
  16. 16.
  17. 17.
  18. 18.
  19. 19.

Continue reading